FDA Approves RSV Shot Despite High Infant Risk - AI Podcast

Dr. Joseph Mercola - Take Control of Your Health

Briana Mercola

Health & Fitness, Health, Alternative Health

4.6 • 1.5K Ratings

🗓️ 17 July 2025

⏱️ 9 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Story at-a-glance

Merck’s respiratory syncytial virus (RSV) shot clesrovimab (Enflonsia) was approved even though 11.71% of babies in the trial experienced serious adverse events, including seizures, brain injury, and death
Infants who got clesrovimab had a 350% higher risk of upper respiratory infections — exactly the type of illness this shot claims to prevent
The injection is given in a single, fixed dose regardless of infant weight, putting smaller, younger babies at greater risk due to disproportionately high exposure
Babies who received the shot had a threefold increase in severe neurological reactions compared to those given a placebo
Only about 25 babies in the U.S. succumb to RSV each year, making the known risks of clesrovimab far outweigh the threat the virus poses to most children

Transcript

Click on a timestamp to play from that location

0:00.0	11.71%, nearly one in nine infants in Merck's Klesrovimab trial, suffered serious reactions,
0:07.0	including seizures, brain injury, and even death.
0:11.0	Does that sound like protection to you?
0:13.0	Welcome to Dr. Mercola's cellular wisdom.
0:16.0	Stay informed with quick, easy-to-listen summaries of our latest articles, perfect for when you're on the go.
0:21.0	No reading required.
0:22.5	Subscribe for free at Mercola.com for the latest health insights.
0:26.0	Hello, and welcome to Dr. Mercola's cellular wisdom.
0:30.7	Today we're examining what the FDA just approved for babies across the country.
0:35.2	When a product claims to shield your child yet raises the risk of the very illnesses it
0:39.3	targets, you deserve the full picture. We'll lay out exactly what the Klesra-Vimab data
0:44.6	show so you can decide whether this shot belongs anywhere near your newborn.
0:49.1	RSV, or respiratory-sensical virus, is so common that almost every child catches it by age two,
0:56.4	yet only about 25 U.S. infants die from it each year.
1:00.7	Despite that low mortality, regulators fast-tracked a one-size-fits-all dose,
1:05.7	105 milligrams, into every infant, whether your baby weighs 12 pounds or barely five.
1:11.6	Uniform dosing sounds efficient, but in pharmacology dose matters more than convenience.
1:16.6	Tiny preterm babies will circulate a far higher concentration of drug than a chunky six-month-old.
1:23.6	Dr. Peter Selly, who combed through the data, warns that side effects rise sharply with exposure,
1:29.3	so the smallest infants shoulder the greatest risk.
1:33.3	Let's look at the numbers.
1:34.3	Out of 2,409 healthy babies injected with Klesrovimab, 3 died versus 1 death among the 1202
	...

Please login to see the full transcript.

Previous episode

Disclaimer: The podcast and artwork embedded on this page are from Briana Mercola, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Briana Mercola and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.